ADS-5102 Phase 2/3 Initiated
 

Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinson's Disease

The Sacramento Bee, Adamas Pharmaceuticals, Inc., Published: Wednesday, Sep. 28, 2011 - 4:11 am

EMERYVILLE, Calif., Sept. 28, 2011 -- /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has initiated a Phase 2/3 clinical trial of its proprietary investigational drug ADS-5102 (amantadine HCl extended release) for the treatment of levodopa induced dyskinesia (LID) in patients with Parkinson's disease. Called EASED™ (Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia), this study will evaluate the safety and effectiveness of three dose levels of ADS-5102 in the treatment of LID.